Relapse after HSCT 2021 | Positioning CAR T-cell therapy for hematological malignancies
Christoph Schmid, MD, University of Augsburg, Augsburg, Germany, discusses the use of chimeric antigen receptor (CAR) T-cell therapy for the treatment of hematological malignancies. Dr Schmid comments on the lack of data on CAR T-cell therapy as consolidation following allogeneic hematopoietic stem cell transplant (alloHSCT). This interview took place at the 2021 Relapse After HSCT² Workshop in New York, NY.
Transcript (edited for clarity)
CAR T-cell, as the name says, it’s a chimera, it’s a T-cell with an immunoglobulin on the surface. We all know that it’s the most exciting success adoptive immunotherapy has made at any time for, in particular, in lymphatic diseases within CD19-directed CARs. That’s where we are at the moment.
Some more CARs have been developed, for example, multiple myeloma. There are some studies ongoing in solid tumors...
CAR T-cell, as the name says, it’s a chimera, it’s a T-cell with an immunoglobulin on the surface. We all know that it’s the most exciting success adoptive immunotherapy has made at any time for, in particular, in lymphatic diseases within CD19-directed CARs. That’s where we are at the moment.
Some more CARs have been developed, for example, multiple myeloma. There are some studies ongoing in solid tumors. What we are still missing is a CAR effective for myeloid diseases. With respect to relapse prevent, we do not have so many data that have used CAR T-cells as consolidation after allogeneic transplantation. The studies I have been showing use just the opposite approach, meaning CAR T-cell as a bridge to transplant or can say allo-transplant is a consolidation or maintenance after CAR T-cell therapy. That sequence, they are very promising data that allowed to report on long-term outcome over survival leukemia-free survival of 50 to 60% in advanced lymphoblastic leukemias.
Read more...
Disclosures
Christoph Schmid, MD, has received research and travel grants from Novartis, Roche, Abbvie and Neovii; honoraria and speakers bureau from Novartis, Roche, BMS and Eurocept; and is also on the advisory boards of Novartis, Daichii, Eurocept and Roche.
